• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Verve Therapeutics Inc.

    2/27/25 8:16:08 AM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VERV alert in real time by email
    S-8 1 d919693ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 27, 2025

    Registration No. 333-  

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    VERVE THERAPEUTICS, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   82-4800132

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

    201 Brookline Avenue, Suite 601

    Boston, Massachusetts

      02215
    (Address of Principal Executive Offices)   (Zip Code)

    2021 Stock Incentive Plan

    Amended and Restated 2021 Employee Stock Purchase Plan

    (Full Title of the Plan)

    Sekar Kathiresan, M.D.

    Chief Executive Officer

    Verve Therapeutics, Inc.

    201 Brookline Avenue, Suite 601

    Boston, Massachusetts 02215

    (Name and Address of Agent For Service)

    (617) 603-0070

    (Telephone Number, Including Area Code, of Agent For Service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    STATEMENT OF INCORPORATION BY REFERENCE

    This Registration Statement on Form S-8, relating to the 2021 Stock Incentive Plan (the “2021 Plan”) and the Amended and Restated 2021 Employee Stock Purchase Plan (together with the 2021 Plan, the “Plans”) of Verve Therapeutics, Inc. (the “Registrant”), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Pursuant to General Instruction E to Form S-8, except as otherwise set forth below, this Registration Statement incorporates by reference the contents of (i) the Registration Statement on Form S-8, File No. 333-257175, filed by the Registrant with the Securities and Exchange Commission (the “SEC”) on June  17, 2021 relating to the 2018 Equity Incentive Plan and the Plans, (ii) the Registration Statement on Form S-8, File No. 333-263518, filed by the Registrant with the SEC on March 14, 2022 relating to the Plans, (iii) the Registration Statement on Form S-8, File No.  333-270207, filed by the Registrant with the SEC on March 2, 2023 relating to the Plans, and (iv) the Registration Statement on Form S-8, File No.  333-277385, filed by the Registrant with the SEC on February 27, 2024 relating to the 2024 Inducement Stock Incentive Plan and the Plans, and the information required by Part II is omitted, except as supplemented by the information set forth below.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

      Item 8.

    Exhibits.

    The following exhibits are incorporated herein by reference:

     

    Exhibit
    Number
      

    Description

    4.1    Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40489) filed with the SEC on June 21, 2021).
    4.2    Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40489) filed with the SEC on February 17, 2023).
    5.1*    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant.
    23.1*    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1).
    23.2*    Consent of Ernst and Young LLP, independent registered public accounting firm.
    24.1*    Power of attorney (included on the signature pages of this registration statement).
    99.1    2021 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-256608) filed with the SEC on June 14, 2021).
    99.2    Amended and Restated 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.7 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-256608) filed with the SEC on June 14, 2021).
    107*    Filing Fee Table.

     

    *

    Filed herewith


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts on this 27th day of February, 2025.

     

    Verve Therapeutics, Inc.
    By:  

    /s/ Sekar Kathiresan

      Sekar Kathiresan
      Chief Executive Officer

    POWER OF ATTORNEY AND SIGNATURES

    We, the undersigned officers and directors of Verve Therapeutics, Inc., hereby severally constitute and appoint Sekar Kathiresan, Allison Dorval and Andrew Ashe, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Verve Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature         Title    Date

    /s/ Sekar Kathiresan

          Chief Executive Officer, Director (Principal Executive Officer)    February 27, 2025
    Sekar Kathiresan

    /s/ Allison Dorval

    Allison Dorval

          Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)    February 27, 2025

    /s/ Burt Adelman

          Director    February 27, 2025
    Burt Adelman

    /s/ Lonnel Coats

          Director    February 27, 2025
    Lonnel Coats

    /s/ Alexander Cumbo

          Director    February 27, 2025
    Alexander Cumbo

    /s/ Michael MacLean

          Director    February 27, 2025
    Michael MacLean

    /s/ Sheila Mikhail

          Director    February 27, 2025
    Sheila Mikhail


    /s/ Jodie Morrison

          Director    February 27, 2025
    Jodie Morrison         

    /s/ Ourania Tatsis

          Director    February 27, 2025
    Ourania Tatsis         

    /s/ Krishna Yeshwant

          Director    February 27, 2025
    Krishna Yeshwant
    Get the next $VERV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VERV

    DatePrice TargetRatingAnalyst
    4/15/2025Neutral → Overweight
    Cantor Fitzgerald
    4/8/2024$15.00Buy
    H.C. Wainwright
    4/13/2023$29.00Buy
    Canaccord Genuity
    2/1/2023$21.00Neutral
    Cantor Fitzgerald
    12/15/2022$13.00Sell
    Goldman
    10/6/2022$48.00Neutral
    Credit Suisse
    8/25/2022$32.00 → $56.00Hold → Buy
    Stifel
    6/17/2022$48.00Outperform
    BMO Capital Markets
    More analyst ratings

    $VERV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results

      Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9 Mean reduction in LDL-C of 53%, with a maximum reduction of 69%, observed after a single infusion of VERVE-102 in the 0.6 mg/kg dose cohort in the Heart-2 clinical trial Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3 continues to progress with a program update expected in the second half of 2025 Cash, cash equivalents, and marketable securities of approximately $500 million; cash runway into mid-2027 BOSTON , May 14, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic med

      5/14/25 7:00:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      BOSTON , May 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on April 30, 2025, the company granted equity awards to seven new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 134,860 shares of the company's common stock and an aggregate of 65,398 restricted stock units (RSUs). The options have an exercise price of $5.67 per share, which is equa

      5/2/25 4:05:00 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

      Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related serious adverse events and no clinically significant changes in ALT or platelets observed at any dose level among 14 participants VERVE-102 utilizes a proprietary GalNAc-LNP which has demonstrated a potentially best-in-class safety profile In the second half of 2025, Verve expects to report final Heart-2 dose escalation data, dose the first patient in a Phase 2 clinical trial for VERVE-102, and receive a decision from Eli Lilly and Company for th

      4/14/25 7:00:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Leadership Updates

    Live Leadership Updates

    See more
    • Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

      WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

      4/1/25 7:00:00 AM ET
      $ABOS
      $CLYM
      $LENZ
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer

      BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Frederick "Fred" T. Fiedorek, M.D., as chief medical officer (CMO). Andrew Bellinger, M.D., Ph.D., the current chief scientific officer (CSO) and CMO, will transition to the role of CSO. "We are excited by the continued expansion of the Verve team and the execution of a plan to become a multi-product clinical-stage company," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. "Our heart-1 clinical trial is well underway, wi

      9/18/23 6:30:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. "Bo" Cumbo, to its Board of Directors

      CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Alexander G. "Bo" Cumbo, chief executive officer and president of AavantiBio, Inc., has joined the company's board of directors. "Bo is a highly experienced industry executive with a well-established track record of leading pharmaceutical and life sciences companies through critical processes in drug development and commercial execution," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. "As we focus on continued execution of our regulatory

      6/13/22 6:30:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Verve Therapeutics Inc.

      SC 13G - Verve Therapeutics, Inc. (0001840574) (Subject)

      11/18/24 5:23:52 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verve Therapeutics Inc.

      SC 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)

      11/12/24 5:52:40 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verve Therapeutics Inc.

      SC 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)

      11/4/24 1:52:43 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    SEC Filings

    See more
    • SEC Form EFFECT filed by Verve Therapeutics Inc.

      EFFECT - Verve Therapeutics, Inc. (0001840574) (Filer)

      5/15/25 12:15:05 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Verve Therapeutics Inc.

      10-Q - Verve Therapeutics, Inc. (0001840574) (Filer)

      5/14/25 7:30:21 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Verve Therapeutics, Inc. (0001840574) (Filer)

      5/14/25 7:15:09 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Financials

    Live finance-specific insights

    See more

    $VERV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

      Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related serious adverse events and no clinically significant changes in ALT or platelets observed at any dose level among 14 participants VERVE-102 utilizes a proprietary GalNAc-LNP which has demonstrated a potentially best-in-class safety profile In the second half of 2025, Verve expects to report final Heart-2 dose escalation data, dose the first patient in a Phase 2 clinical trial for VERVE-102, and receive a decision from Eli Lilly and Company for th

      4/14/25 7:00:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia

      LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses Safety Profile Supports Continued Development of VERVE-101 Enrollment Ongoing in the 0.45 mg/kg and 0.6 mg/kg Cohorts with Plans to Initiate Expansion Cohort in 2024 Company to Host Conference Call and Webcast Today at 6:30 p.m. ET BOSTON, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced first human proof-of-concept data for in vivo base editing from the ongoing hear

      11/12/23 3:30:00 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ashe Andrew D. bought $475,760 worth of shares (76,000 units at $6.26), increasing direct ownership by 29% to 342,509 units (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      5/15/24 5:30:07 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Yeshwant Krishna bought $18,000,000 worth of shares (1,800,000 units at $10.00) (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      12/5/23 4:30:09 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Administrative Officer Nickerson Joan converted options into 9,315 shares and sold $11,525 worth of shares (2,777 units at $4.15), increasing direct ownership by 60% to 17,420 units (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      4/3/25 5:00:17 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Ashe Andrew D. converted options into 9,000 shares and sold $11,126 worth of shares (2,681 units at $4.15), increasing direct ownership by 2% to 348,828 units (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      4/3/25 5:00:14 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Kathiresan Sekar converted options into 33,000 shares and sold $40,761 worth of shares (9,822 units at $4.15), increasing direct ownership by 7% to 346,686 units (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      4/3/25 5:00:19 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Verve Therapeutics upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded Verve Therapeutics from Neutral to Overweight

      4/15/25 8:57:58 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Verve Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Verve Therapeutics with a rating of Buy and set a new price target of $15.00

      4/8/24 8:03:41 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Verve Therapeutics with a new price target

      Canaccord Genuity initiated coverage of Verve Therapeutics with a rating of Buy and set a new price target of $29.00

      4/13/23 7:37:44 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care